

PRIMARY CARE ADVISORY COUNCIL (PCAC) MEETING AGENDA

**SEPTEMBER 16TH, 2024
12PM TO ADJOURNMENT**

This meeting will be held online or by phone. The online and phone meeting details are:

Virtual Teams Meeting Address Link:

https://teams.microsoft.com/l/meetup-join/19%3ameeting_ODE4NjA1YjEtZmZkNC00NjkxLWFkNTktNTE0YTRmMjY3ZTUw%40thre%20ad.v2/0?context=%7b%22Tid%22%3a%22e4a340e6-b89e-4e68-8eaa-1544d2703980%22%2c%22Oid%22%3a%222219c698-6fc5-473d-98d6-957c70e6a61a%22%7d

Or call in (audio only)

+1 775-321-6111 United States, Reno
Phone Conference ID: 675 644 458#

This meeting is recorded pursuant to the Nevada Open Meeting Law (Nevada Revised Statutes Chapter 241). Agenda items may be taken out of order, combined for consideration, and/or removed from the agenda at the Chairperson's discretion. A break may be scheduled at the Chairperson's discretion.

1. Call to order/roll call – Staff
2. Possible Action: Review and possible approval of minutes from the June 20, 2024 meeting – Chairperson

PUBLIC COMMENT

3. Possible Action: Discussion and possible action to make recommendation to the Administrator for the Division of Public and Behavioral Health regarding a J-1 Visa Waiver Letter of Support for Dr. Ragoonanan – Tarryn Emmerich-Choi, Primary Care Manager, PCO

PUBLIC COMMENT

4. Public Comment: No Action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on an agenda as an item upon which action will be taken.
5. Adjournment

NOTICE OF THIS MEETING AGENDA HAS BEEN POSTED AT THE FOLLOWING
LOCATIONS:

Nevada Public Notice website: <https://notice.nv.gov>
Division of Public and Behavioral Health (DPBH), Primary Care Office website:
[https://dpbh.nv.gov/Boards/PCO/Meetings/2024/Primary_Care_Advisory_Coun
cil_FFY2024Meetings/](https://dpbh.nv.gov/Boards/PCO/Meetings/2024/Primary_Care_Advisory_Council_FFY2024Meetings/)
[DPBH – 4150 Technology Way, Carson City, NV 89706](#)

We are pleased to make reasonable accommodations for individuals who wish to attend this meeting. If special arrangements or equipment are necessary, please notify the Nevada Primary Care Office at nvpco@health.nv.gov or in writing, at Division of Public and Behavioral Health, Attn: Primary Care Office, 4150 Technology Way, Suite 300, Carson City, NV 89706 or by calling (775) 684-2204 no less than three (3) business days prior to the meeting.

Inquiries regarding the items scheduled for this Council meeting or if a member of the public would like to request the supporting material for this meeting, please contact Nevada Primary Care Office at nvpco@health.nv.gov or (775) 684-2204.

DRAFTMINUTES
June 20, 2024
10:00AM to Adjournment

TELECONFERENCE:

In accordance with Governor Sisolak's Declaration of Emergency Directive 006; Subsection 1; The requirement contained in NRS 241.023 (1) (b) that there be a physical location designated for meetings of public bodies where members of the public are permitted to attend and participate is suspended.

COUNCIL MEMBERS PRESENT:

Dr. Susan VanBeuge
Dr. Donald Campbell
Gerald Ackerman
Kathleen Stodtmeister
Julie Clyde

COUNCIL MEMBERS NOT PRESENT:

Dr. Amir Qureshi
Nancy Bowen
Sarah Watkins (sent designee)

DPBH/DHCFP STAFF PRESENT:

Tarryn Emmerich-Choi, Health Resource Analyst, PCO
Beth Schimank, Management Analyst, PCO

OTHERS PRESENT:

1. Roll call and confirmation of quorum.

2. Approval of minutes:

Gerald Ackerman asked if there were any additions or corrections to the minutes from the April 15th, 2024 meeting. No recommendations were made.

First Motion: Julie Clyde moves to pass the approval of minutes

Second Motion: Dr. VanBeuge seconds

Motion: Passes Unanimously

3. Recommendation to the Administrator for the Division of Public and Behavioral Health regarding a J-1 Physician Visa Waiver Letter of Support for Dr. Al-Nattah. Tarryn Emmerich-Choi presented a summary handout of the completed application.

Member Comment: none

Public Comment: none

First Motion: Julie Clyde moves to approve

Second Motion: Dr. Campbell seconds

Motion: Passes Unanimously

- 4. Recommendation to the Administrator for the Division of Public and Behavioral Health regarding a J-1 Physician Visa Waiver Letter of Support for Dr. Adrianza.** Tarryn Emmerich-Choi presented a summary handout of the completed application.

Member Comment: Gerald Ackerman mentions that Infectious Disease is a specialty that is really needed in the northern region and he is excited to see them.

Public Comment: none

First Motion: Julie Clyde moves to approve

Second Motion: Dr. Campbell seconds

Motion: Passes Unanimously

- 5. Recommendation to the Administrator for the Division of Public and Behavioral Health regarding a J-1 Physician Visa Waiver Letter of Support for Dr. Lall.** Tarryn Emmerich-Choi presented a summary handout of the completed application.

Member Comment: none

Public Comment: none

First Motion: Dr. Campbell moves to approve

Second Motion: Julie Clyde seconds

Motion: Passes Unanimously

- 6. Recommendation to the Administrator for the Division of Public and Behavioral Health regarding a J-1 Physician Visa Waiver Letter of Support for Dr. Novoa.** Tarryn Emmerich-Choi presented a summary handout of the completed application. Gerald Ackerman asks for confirmation of the address of the practice in Elko.

Member Comment: Gerald Ackerman states that Obstetrics and Gynecology are also much needed in the northern areas of Nevada and he is

glad to see them on the agenda.

Public Comment: none

First Motion: Julie Clyde moves to approve

Second Motion: Donald Campbell seconds

Motion: Passes Unanimously

7. Member or Public Comment

Gerald asks Tarryn Emmerich-Choi if there are any PCO updates, Tarryn mentions that the Primary Care Office only has 3 more Conrad-30 slots left this cycle. Gerald Ackerman and Dr. VanBeuge both congratulate the PCO and their efforts.

8. Adjournment

The meeting adjourned at 10:18 a.m.

Nevada Conrad 30 J-1 Physician Visa Waiver Program Application Attestation

Complete and check all applicable fields, corresponding boxes and enter all required information:

Candidate's Information:

Candidate's Full Name: Dristhi Servani Ragoonanan
Residency Discipline: Pediatrics
Residency Timeframe: 2015 to 2018
Location of Residency: Jackson Memorial Hospital in affiliation with Leonard M Miller School of Medicine, University of Miami, Florida
Fellowship(s)/Specialty: Pediatric Hematology and Oncology
Fellowship(s) Timeframe1: 2018 to 2021
Location of Fellowship(s)1: University of Texas MD Anderson Cancer Center, Texas

Employer's Information:

Employer's Full Name: Cure 4 The Kids Foundation
Employer's Address: 1 Breakthrough Way, Las Vegas, NV 89135
Practice Site #1: Cure 4 The Kids Foundation
Practice Site #1 Address: 1 Breakthrough Way, Las Vegas, NV, 89135
Number of Hours Candidate will practice at site to meet 40 hours per week: 40 hours plus on call time
Select and input all that apply:
 Practice Site #1 HPSA (#HPSA#) Practice Site #1 MUA (#MUA#) Flex spot
 Federally Qualified Health Center (FQHC) Tribal Health Center
 Rural Health Clinic (RHC) Primary Care Clinic for a Rural Hospital

Practice Site #2*: N/A
Practice Site #2 Address: N/A
Number of Hours Candidate will practice at site to meet 40 hours per week: Number of Hours site#2
Select all that apply:
 Practice Site #2 HPSA (#HPSA#) Practice Site #2 MUA (#MUA#) Flex spot
 Federally Qualified Health Center (FQHC) Tribal Health Center
 Rural Health Clinic (RHC) Primary Care Clinic for a Rural Hospital

More than two additional practice sites: Yes No

If additional practice sites, please copy and add all additional practice locations here or at end of form

Official Legal Representative and Contact Person for Application:

Contact Name: Michael R. Jarecki // Jarecki Law Group, LLC
Contact Mailing Address: 53 W. Jackson Blvd, Suite 1515 Chicago, IL 60604
Contact e-mail: mike@jareckilaw.com

Nevada Conrad 30 J-1 Physician Visa Waiver Program Application Attestation

Contact telephone: (312) 922-1111

Official Contact Person for Employment Verification and Site Information:

Contact Name: Christine Tonn
Contact Mailing Address: 1 Breakthrough Way Las Vegas NV, 89135
Contact e-mail: ctonn@cure4thekids.org
Contact telephone: (702) 691-5703

Employer and Candidate, as identified above, seek a letter of support from the Physician Visa Waiver Program and requests the Division of Public and Behavioral Health to forward the J-1 Visa Waiver application to the U.S. Department of State as a State Health Agency request, per DS-3035. Employer and Candidate have agreed to comply with the duties set forth in Chapter 439A of the Nevada Revised Statutes (NRS) and Nevada Administrative Code (NAC) and to cooperate with the Physician Visa Waiver Program.

Employer and Candidates have provided all necessary information for review of this application by the Primary Care Council including the following:

- Copy of the contract between the Employer and Candidate;
- Copy of the Candidate curriculum vitae and passport pages;
- Letter from Employer: description of the Candidate's qualifications, responsibilities and how this employment will satisfy important unmet health care needs within the designated area;
- Summation tables identifying the breakdown of patient visits billed by payment category;
- Documentation of employer recruitment efforts for US citizens for two months prior to submission of the application, UNLESS the requirement was waived for a rural employer with emergent needs;
- Long-range retention plans which include the following: CME benefit, competitive salary and paid time off.
- Copy of letter from the Nevada State Board of Medical Examiners (NSBME) acknowledging Candidate's application for medical licensure;
- INS Form G-28 OR letter from a law office if the candidate has an attorney OR a statement that the applicant does not have an attorney;
- Copies of all DS-2019's "Certificate of Eligibility for Exchange Visitor (J-1 Visa Waiver) Status" (INS form(s) I-94 for the candidate and any family members; proof of passage of examinations required by Bureau of Criminal Investigation (BCI); transcripts for all 3 sections of *United States Medical Licensing Examinations* (USMLE); and certification from *Educational Commission for Foreign Medical Graduates* (ECFMG).

In signing below, an authorized representative of the Employer and the Candidate declares under penalty of perjury that all statements submitted with this application are true and accurate and this application complies with the requirements of NRS 439A.175 and NAC 439.730 including as follows:

All practices sites where the Candidate will practice:

Nevada Conrad 30 J-1 Physician Visa Waiver Program Application Attestation

- Are located in a federally designated Primary Care HPSA, MUA/P or a site approved by the state as a geographic exception or a flex slot (Public Law 108-441) to address the underserved;
- Accept Medicare, Medicaid assignment and Nevada Checkup;
- Offer a sliding discount fee schedule and a minimum fee based on family size & income; and
- Has a policy stating all patients will receive treatment, regardless of their ability to pay which is either posted at the site or provided to the patients.

The contract between the Employer and the Candidate provides the following (verify and enter missing data):

- Candidate agrees to provide services during 3 -year waiver obligation;
- Candidate will provide services 40 hours per week minimum plus on-call time;
- The salary meets or exceeds the prevailing wage for that area and for physicians of that specialty as reported by the Foreign Labor Certification Center, Department of Labor, (<http://www.flcdatacenter.com>): Prevailing wage (FLC Median wage for Pediatricians, General: \$\$203,237./ Contracted wage \$240,000. base pay
- The amount of time off for vacation, sick leave and for Continuing Medical Education is included. The employer shall maintain records to show the amount of time-off requested and the amount of time taken.
- Does ~~not contain a "non-compete"~~ clause that would prohibit the J-1 Visa Waiver physician from opening a new clinic, or working in a clinic in that shortage area upon completing the three-year commitment;
- Conditions for termination of the contract, for both the physician and employer, are included. A "no-cause" termination is not allowed;
- Liquidated damages (suggested to be under \$50,000) in the event that the physician or employer terminates the contract before three years is included in the contract - Employer \$N/A /Physician \$25,000;
- Agreement to begin employment at the stated practice site within 90 days of receiving a waiver from the United States Citizenship and Immigration Services (USCIS). During the 90 days, the physician must obtain the required licenses from the Nevada State Board of Medical Examiners, the Drug Enforcement Agency, the State Board of Pharmacy, and any other licenses as may be required for the physician to practice medicine in Nevada; and
- A statement that the physician agrees to meet the requirements set forth in section 214(l) of the Immigration and Nationality Act.

Please note in accordance with NRS Chapter 239, all public records, the contents not otherwise declared by law to be confidential, shall be open for inspection or to obtain copies.

Nevada Conrad 30 J-1 Physician Visa Waiver Program Application Attestation

By signing below, I hereby attest that the above requirements have been met and I hereby agree to abide by all the program policies and rules as described in NRS and NAC and as further required under the Rights and Responsibilities located at the Divisions website at: <http://dpbh.nv.gov/Programs/Conrad30/Conrad30-Home/>.

Authorized Employer:

Alliance For Childhood Diseases dba Cure 4 The Kids Foundation
Employer Company/Business Name


Christine Tonn CEO
Employer Representative Name (First/Last) Title

[Signature] 7/10/2024
Employer Signature Date

NOTARY PUBLIC:

State of: Nevada
County of: Clerk
Subscribed and Sworn before me on this 10 day of July, 20 24

Jodie Marenfeld
Notary Signature
My Commission Expires: 02/03/2026



Candidate/Physician:


Dristhi Servani Ragoonanan Dr.
Candidate Name (First/Last) Title

Dristhi Servani Ragoonanan 07/13/2024
Candidate Signature Date

NOTARY PUBLIC:

State of: Texas
County of: Harris
Subscribed and Sworn before me on this 13th day of July, 20 24

[Signature]
Notary Signature
My Commission Expires: 10/20/2027



Electronically signed and notarized online using the Proof platform.



- iii. Coordinates treatment plans and prescribes various types of treatment, including chemotherapy and immunotherapy
- iv. Prepare and oversee treatment plans, including appropriate dosages
- v. Facilitate direct hospital admissions and care planning, involving specialist, time discharge, and medication coordination
- vi. Facilitate end-of-life discussions and care planning involving specialist, time discharge and medication coordination
- vii. Along with other providers of the center, participate in on-call coverage 24 hours a day, 7 days a week, onsite or offsite by telephone, responding within time frames established by the medical staff and / or Medical Director for emergent, urgent, and routine requests
- viii. Participate in quality improvement activities
- ix. Participate in the resolution of patient, parent, and provider complaints and enhance patient and provider satisfaction as measured by periodic surveys
- x. Maintain excellent working relationships and communication with others physician members of the organization, support personnel, administration, and the Leadership Team
- xi. Participate in Multidisciplinary meetings, Provider meetings, Tumor Board meetings, and NCORP meetings

Tab C

Please see the below charts with respect to the practice site:

Time Period of Report: 01/01/2023 – 12/31/2023		
	Total # of visits for 12 months	% of visits per 12 months
Medicare visits	152	0.8%
Medicaid visits	8,565	46.1%
NV Check-up	98	0.5%
Sliding Fee Scale	0	0.0%
Indigent / Charity	820	4.4%
Other – Not listed above	8,939	
Totals	18,574	51.8%



# of MDs by FTE	8
# of Pas by FTE	1
# of APNs by FTE	5

Dr. Dristhi Ragoonanan's role will help fill a critical healthcare need for pediatric oncology patients. Cure 4 The Kids is the only nonprofit program in the State of Nevada that offers highly specialized medical care to the underserved pediatric population within the state. Cure 4 The Kids currently has six pediatric oncologists and has one additional vacancy for Dr. Dristhi Ragoonanan's position. This is not a hospitalist position.

Dr. Dristhi Ragoonanan is a pediatric hematologist/oncologist. The nearest providers for these patients are:

- CHLA (Los Angeles, CA): 4650 Sunset Blvd, Los Angeles, CA 90027 (297 miles away).
- Phoenix Children's Hospital (Phoenix, AZ): 1919 E. Thomas Rd, Floor 7, Phoenix, AZ 85016 (309 miles away).
- Primary Children's Hospital (Salt Lake City, Utah): 100 Mario Capecchi Dr, Salt Lake City, UT 84113 (441 miles away).

There are four pediatric oncologists in northern Nevada, 450 miles away, who cannot handle the volume of patients they have in addition to serving southern Nevada children.

Tab D: Recruitment and Retention Efforts

Cure 4 The Kids has been actively recruiting qualified pediatric oncologists on an ongoing basis with very little success. Enclosed at Tab D are the following documents regarding recruitment:

1. Copies of the advertisements used by Team Communication and Pediatric Search Partners to recruit a qualified pediatric oncologist.

Additionally, we offer the following as part of our physician retention program:

- Annual bonus incentives and bonuses for completed special projects.
- Employer-paid DEA, Medical Licenses, PALS and other certifications.





CURE 4 THE KIDS
FOUNDATION

A Division of Roseman University of Health Sciences

August 15, 2024

Nevada Primary Care Office
Conrad 30 J-1 Visa Waiver Program
4150 Technology Way, Suite 300
Carson City, NV 89706-2009
CC: nvpco@health.nv.gov

Re: Conrad 30 Flex Slot J-1 Visa for Dr. Dristhi Servani Ragoonanan

To Whom It May Concern:

This letter is written in support of a Conrad 30 J-1 Visa Waiver Flex Slot from the Nevada Primary Care Office for Dr. Dristhi Servani Ragoonanan. Below is information about Alliance for Childhood Diseases dba Cure 4 The Kids Foundation and the importance of adding Dr. Dristhi Ragoonanan, a pediatric hematologist/oncologist, to our clinical team.

I am the CEO of Alliance for Childhood Diseases d/b/a Cure 4 The Kids Foundation, a nonprofit corporation founded in 2007 that serves as Nevada's Childhood Cancer and Rare Disease Treatment Center. The primary approach behind our business model is to create a new kind of healthcare facility: one that blends the best of what corporate healthcare, education, and research has to offer with the generosity, thoughtfulness, and spirit of charity. This hybrid model allows us to function like a traditional professional healthcare entity in terms of clinical outcomes, yet also allows us to humanize our interactions with patients and their families. We continue to aim to be a nationally recognized center of excellence with a regional focus that equips kids and their families to fight diseases. Our goal is never to turn away any child who needs medical attention. This is what makes us unique as Cure 4 The Kids Foundation. Since our inception, Cure 4 The Kids Foundation has made huge strides in pediatric catastrophic diseases. Every year, we expand our services to help as many families in our region as possible.

Cure 4 The Kids is the only nonprofit program in the State of Nevada that offers highly specialized medical care to the underserved pediatric population within the state. Cure 4 The Kids Foundation currently employs 142 individuals and had recent annual revenue of over \$41 million. More information is available on our website: <https://cure4thekids.org/>.

Dr. Dristhi Ragoonanan's role will help fill a critical healthcare need for pediatric oncology patients. Cure 4 The Kids currently has six pediatric oncologists and has one additional vacancy for Dr. Dristhi Ragoonanan's position. Cure 4 The Kids is limited by the physicians in our clinic. This is not a hospitalist position.



CURE 4 THE KIDS FOUNDATION

A Division of Roseman University of Health Sciences

Dr. Dristhi Ragoonanan is a pediatric hematologist/oncologist who is being offered full-time employment. We need physicians like Dr. Ragoonanan to help us serve the large number of patients we see every day. The nearest providers for these patients are Children’s Hospital Los Angeles, which is 297 miles away, Phoenix Children’s Hospital which is 309 miles away, and Primary Children’s Hospital in Utah which is 441 miles away. The two pediatric oncologists in northern Nevada, which is 450 miles away, are just starting with Children’s Oncology Group research and cannot handle the volume of patients they have in addition to serving southern Nevada children.

Due to understaffing in our hematology/oncology team, we have been taking non-billed courtesy calls on a regular basis from Sunrise Hospital. With the addition of Dr. Dristhi and other recent hires, we are looking to expand our coverage to Sunrise. Since we have not been taking billed calls for Sunrise Hospital, we do not have data/patient count information. We have included information on services provided when our providers have been rounding at Summerlin Hospital based on 2023 data. Provider rounding data below includes visits by our 6 Hematology/Oncology doctors and 1 Nurse Practitioner as part of our provider team. When our provider is scheduled to be on-call, he/she does not carry a full schedule of clinic visits at Cure 4 The Kids as they may be responding to a call during normal business hours.

Time Period of Report for Summerlin Hospital Rounding: 01/01/2023 – 12/31/2023		
	Total # of Visits for 12 months	% of visits per 12-month period
Medicare visits	42	2.2%
Medicaid Visits	1,130	58.2%
Nevada Check-up	51	2.6%
Sliding Fee Scale	0	0.0%
Indigent/Charity	5	0.2%
Other – Not Listed above	715	36.8%
Total Hem/Onc Visits	1,943	

- **Practice site name:** Summerlin Hospital
- **Contact Person:** Kelly Block (C4K Contact is Christine Tonn; 702-691-5703)
- **Practice site mailing and physical address:** 657 N. Town Center Drive, Las Vegas, NV 89144
- **HPSA and / or MUA / P designation number:** Not Applicable. Cure 4 The Kids Foundation is applying for a Flex Slot.
- **Telephone:** (702) 233-7000





CURE 4 THE KIDS FOUNDATION

A Division of Roseman University of Health Sciences

- **Fax:** (702) 853-8374
- **Email address:** Kelly.block@uhsinc.com

- **Practice site name:** Sunrise Hospital
- **Contact Person:** AnneMarie Witecki (C4K Contact is Christine Tonn; 702-691-5703)
- **Practice site mailing and physical address:** 3186 S. Maryland Pkwy, Las Vegas, NV 89109
- **HPSA and / or MUA / P designation number:** Not Applicable. Cure 4 The Kids Foundation is applying for a Flex Slot.
- **Telephone:** (702) 961-5000
- **Fax:** (844) 866-2751
- **Email address:** AnneMarie.Witecki@hcahealthcare.com

Cure 4 The Kids requests that the Nevada Division of Public and Behavioral Health (NDPBH) act as an "Interested Government Agency" and recommend a waiver for Dr. Dristhi Ragoonanan. The practice site where she would be working is Alliance for Childhood Diseases dba Cure 4 The Kids Foundation located at 1 Breakthrough Way in Las Vegas, Nevada 89135. The HPSA / MUA / MUP designation number is not applicable as Alliance for Childhood Diseases dba Cure 4 The Kids Foundation is applying for a flex slot.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Please do not hesitate to contact me should you have further questions.

Sincerely,

Christine Tonn
CEO
Cure 4 The Kids Foundation
E-mail: ctonn@cure4thekids.org
Phone: (702) 691-5703
Fax: (702) 732-1080

Enclosures

Dristhi Ragoonanan, MBBS

CURRICULUM VITAE

Present Title and Affiliation

Primary Appointment

Assistant Professor
Department of Pediatrics
The University of Texas MD Anderson Cancer Center, Houston TX

Fellowship Program Director
Pediatric Stem Cell Transplantation and Cellular Therapy
The University of Texas MD Anderson Cancer Center, Houston TX

Citizenship

Trinidad and Tobago

Date of Birth

Address:

Home:

Office: The University of Texas, MD Anderson Cancer Center
1515 Holcombe Blvd Unit 87
Division of Pediatrics
Houston, TX 77030
Phone: 713-632-5087

Email:

EDUCATION AND POSTGRADUATE TRAINING

Degree-Granting Education

Bachelor of Medicine Sciences 07/2005-06/2008
University of the West Indies, St. Augustine, Trinidad and Tobago WI

Bachelor of Medicine and Bachelor of Surgery (M.B.B.S) 07/2005- 07/2010
University of the West Indies, St. Augustine, Trinidad and Tobago WI

Post-Graduate Training

Clinical Internship in the Departments of Pediatrics, General Surgery, 07/2010-07/2011
Internal Medicine and Obstetrics and Gynecology.
San Fernando General Hospital. Trinidad and Tobago

House Officer in the Department of Surgical Subspecialties San Fernando General Hospital. Trinidad and Tobago	08/2011-06/2015
Clinical Residency, Pediatrics University of Miami, Jackson Memorial Hospital, Miami FL	07/2015-06/2018
Clinical Fellowship, Pediatric Hematology Oncology University of Texas, MD Anderson Cancer Center, Houston, TX.	07/2018-06/2021
Clinical Fellowship, Pediatric Stem Cell Transplantation and Cellular Therapy University of Texas, MD Anderson Cancer Center, Houston, TX.	07/2021-Present

CREREDENTIALS

Board Certification

The American Board of Pediatrics, Certificate No 127730	10/2019
The American Board of Pediatrics, Subboard of Pediatric Hematology Oncology No 4145	04/2023

Active Certifications

Educational Commission for Foreign Medical Graduates (ECFMG)	02/2018
Kymriah Certification	08/2018
MD Anderson Cancer Center CARTOX Certification	09/2018
Human Subjects Protection Certificate	10/2018
YESCARTA Certification	08/2020
Pediatric Advanced Life Support	05/2021
Pediatric Advanced Cardiac Life Support	05/2023
Basic Life Support	05/2023
Good Clinical Practice Certificate	02/2022
Advanced Cardiac Life Support	04/2022

Licensures

Active

Trinidad and Tobago Medical Physician License	2011-Present
Texas Physician in Training Medical License	2018-Present
Texas Medical Physician License (#T7010)	04/29/2022-05/31/2024
Georgia Composite Medical Board (#96570)	8/2/2023-1/31/2025
Oklahoma State Board of Medical Licensure & Supervision (#41974)	7/5/2023-7/1/2024
Washington Medical Commission (IMLC.MD.61463450)	6/29/2023-1/18/2024
Tennessee Board of Medical Examiners (#69061)	06/26/2023-1/31/2026
Louisiana Medical Board (# 337573)	06/27/2023-1/31/2024
Arizona Medical Board (70803)	06/27/2023-5/18/2024
Alabama Board of Medical Examiners(#46735)	06/26/2023-12/31/2023
Mississippi State Board Of Medical Licensure (#32168)	08/28/2023-06/30/2024

Inactive

Philadelphia Medical Physician License	10/15/2018-12/31/2020
--	-----------------------

Experience/Service

Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX	09/2022-Present
---	-----------------

Educational Appointments

Fellowship Program Director 08/2023- Present
Pediatric Stem Cell Transplantation and Cellular Therapy
The University of Texas MD Anderson Cancer Center, Houston TX

Administrative Appointments/Responsibilities

Fellow Recruitment for Pediatric Hematology/Oncology Fellowship 08/2020 – 12/2020
MD Anderson Cancer Center, Houston, TX, USA

Chief Fellow, Pediatric Hematology/Oncology 07/2020 – 06/2021

MD Anderson Cancer Center, Houston, TX, USA
Team Leader: Pediatric Stem Cell Therapy/Immunotherapy 02/2022-Present
MD Anderson Cancer Center, Houston, TX, USA

Organization of Conference

Facilitator and Planning Committee Member for the Critical Care Management of Pediatric HSCT and Cell Therapy Patients Workshop 02/20/2019
Houston, TX

Institutional Committee Activities

Graduate Medical Education House Staff Senate Member 06/2019-07/2020

Secretary of the Graduate Medical Education House Staff Senate (HSS) 06/2020- 07/2021
MD Anderson Cancer Center, Houston, TX, USA

Pediatric Hematology Oncology Fellowship Evaluation Committee 09/2020 – 06/2021
MD Anderson Cancer Center, Houston, TX, USA

Trainee Benefits Committee 09/2020 – Present
MD Anderson Cancer Center, Houston, TX, USA

SARS-CoV-2 Associated Multisystem Inflammatory Syndrome Working Management Algorithm Task Force 10/2020- Present

Coordinated and led a multidisciplinary team to create an institutional algorithm for the management of multisystem inflammatory syndrome (MIS) in children and adults with malignancies based on available evidence. Responsible for reviewing emerging literature regarding MIS in adults and children to update the established institutional algorithm as new data emerges.

President of the Graduate Medical Education House Staff Senate (HSS) 07/2021- Present
MD Anderson Cancer Center, Houston, TX, USA

Diversity, Equity and Inclusion Champion 2022 02/2022-Present
MD Anderson Cancer Center, Houston, TX, USA

Invited Speaker

Panelist, Facilitator and Planning Committee Member for the Contemporary Critical Care Complications of Stem Cell Transplant(SCT) and Cellular Therapies(CT) Virtual Conference 03/2021

Invited speaker on an international panel of experts for the Contemporary Critical Care Complications of Stem Cell Transplant (SCT) and Cellular Therapies(CT) Virtual Conference (2021). For this virtual conference, I collaborated with members of the Association for Pediatric Hematology Oncology Nursing (APHON), the Pediatric Acute Lung Injury & Sepsis Investigators (PALISI)- Stem Cell Transplantation and Cellular Therapy Subgroup and the Pediatric Diseases Working Party of the European Society of Blood and

Marrow Transplantation to concurrently train > 100 oncology and critical care nurses, fellows and other clinicians both nationally and internationally on real-world clinical scenarios of Sinusoidal Obstructive Syndrome(SOS) and Cytokine Release Syndrome(CRS) (two potentially fatal complications of HCT) through actual patient videos and lifelike virtual reality simulations. As an invited expert panelist, I moderated presentations, provided expert advice, debriefed and led discussion post virtual reality scenarios.

Management of Pediatric Patients Undergoing Immunotherapy for Solid and Hematological Malignancies

American Society Radiation Oncology (ASTRO) San Antonio, TX USA

10/2022

HONORS AND AWARDS

National

National Tertiary Education Scholarship

Government of Trinidad and Tobago

06/2004

David C. Leach Award (Team Member)

03/2022

National Award: Accreditation Council for Graduate Medical Education (ACGME)

(This award acknowledges and honors residents, fellows, and resident/fellow teams and their contributions to graduate medical education)

Institutional

Excellence in Bone Marrow Transplant Award

Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA

06/2019

Excellence in Cellular Therapy Award

Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA

06/2020

Excellence in Leukemia/Lymphoma Award

Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA

06/2020

Best Oral Abstract Presentation

Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA

05/2021

Excellence in Scholarly Activity

Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA

05/2021

Excellence in Stem Cell Transplant Award

Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA

05/2021

Excellence in Hematology Award

Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA

05/2021

Endowed Fellowship Award

“Shannon Timmins Fellowship for Pediatric Leukemia Research”

MD Anderson Cancer Center, Houston, TX, USA

05/2021

Resident/Fellow Excellence in Teamwork Award

Office of Graduate Medical Education. MD Anderson Cancer Center, Houston, TX, USA

03/2022

RESEARCH

Research Outside of Current Institution

**Predictors of Outcomes for Patients with Acute Lymphoblastic Leukemia
Post Chimeric Antigen Receptor T-Cell Therapy**

02/2020

Center for International Blood and Marrow Transplant Research. Orlando, FL

Aim: To investigate the predictors of outcomes for patients with acute lymphoblastic leukemia post chimeric antigen receptor T-cell (CAR-T) therapy, with the primary aim of establishing remission rates, survival outcomes and the effect of cytogenetics, demographic and disease status. For this instrumental study, data accrual and analysis are underway of over 600 patients from 83 centers. This will be the largest population of pediatric, adolescent and young adult (AYA) patients undergoing CAR-T therapy ever published in the USA.

Protocols

Funded

Principal Investigator, POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), 10/2021

Principal Investigator, Multicenter, open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy 2017-0771, 2018-present, ATARA (sponsor)

Principal Investigator, An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases, 2020-0375, 2021-present, ATARA (sponsor)

Principal Investigator, A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High Risk Solid Tumors, 2020-0496, 2020-present, Departmental/Investigator initiated

Principal Investigator, A multi-institutional study of TGFb; imprinted, ex-vivo expanded universal donor NL cell infusion as adoptive immunotherapy in combination with Gemcitabine, Docetaxel in patients with relapsed or refractory pediatric bone and soft tissue sarcomas. The TiNKS Trial, 2022-0995, national Pediatric Cancer Foundation, 2022-Present

Collaborator, Phase I study of ex-vivo expanded allogeneic NK cells for the treatment of pediatric solid tumors, 2017-0085, 2018-present, Departmental/Investigator initiated

Collaborator A Phase II Pilot Trial To Estimate Survival After A Non-Total Body Irradiation (TBI) Based Conditioning Regimen In Patients Diagnosed With B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation, 2018-0964, 2019-present, Children's Hospital Los Angeles

Collaborator, A Phase ½, Open-label, Single Arm Multicohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects with Relapsed/refractory B-ALL and B-NHL (TRANSCEND PEDALL), Celgene, 2021-1030, 2021-present

Collaborator, A phase 1b, open label, single-arm, multicenter study to evaluate the safety, efficacy and pharmacokinetics of multiple doses of ELA026 in adults and adolescents with secondary hemophagocytic Lymphohistiocytosis (sHLH), Electra Therapeutics, 2022-0639, 2022-Present

Collaborator, A First-In-Human Phase 1 Trial of T Cell Membrane-Anchored Tumor Targeted IL12 (Attil12)-T Cell Therapy in Subjects with Advanced/Metastatic Soft Tissue and Bone Sarcoma, Departmental/Investigator initiated

Unfunded

Principal Investigator, The Impact of DNMT3A Mutations in Pediatric and Adolescent and Young Adult Patients with Pediatric Acute Myeloid Leukemia, 2020-1256, 2020-present

Principal Investigator, Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT), 2020-1309, 2021-present

Collaborator, CD19 Chimeric Antigen Receptor T Cell Therapy beyond Clinical Trials: Unique cases presentations and management, PA18-0868, 2018-present

Collaborator: Data-Driven Determinants for COVID-19 Oncology Discover Effort (D3CODE) (Protocol ID MDACC 2020-0348)

Publications

1. NJM Dailey Garnes, D **Ragoonanan**, A Aboulhosn
Adenovirus infection and disease in recipients of hematopoietic cell transplantation. Current Opinion in Infectious Disease. Dec 2019 PMID: 31567568
2. F P Tambaro, S.J Khazal, C Nunez, **D Ragoonanan**, P Tewari, D Petropoulos, P Kebriaei, W G Wierda, K M Mahadeo
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T cell therapy. Clinical case Reports April 2020. PMID: 32983475
3. S Khazal, **D Ragoonanan**, C Hosing, L Williams, LJ Medeiros, KM Mahadeo, PA Thompson
Epstein-Barr virus Specific Cytotoxic T Lymphocytes for the Treatment of Severe Epstein-Barr virus Positive Mucocutaneous Ulcer. British Journal of Hematology. April 2020 PMID: 32150641
4. **D Ragoonanan**, S.J Khazal, JWang, A Payne, M Kohorst, A Harden, P Tewari, D Petropoulos, B Shoberu, P Kebriaei, K M Mahadeo, F P Tambaro
Improved Detection of Sinusoidal Obstructive Syndrome Using Pediatric- AYA Diagnostic Criteria and Severity Grading. Bone Marrow Transplantation July 2020. PMID: 32665674
5. S Khatua, LJ Cooper, DI Sandberg, L Ketonen, JM Johnson, ME Rytting, DD Liu, H Meador, P Trikha , RJ Nakkula, GK Behbehani, **D Ragoonanan** , S Gupta, A Kotrotsou , T Idris, EJ Shpall, K Rezvani, R Colen , W Zaky ,DA Lee, V Gopalakrishnan
Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro-oncology. Aug 2020. PMID 32152626
6. A Harden, **D Ragoonanan (co-first author)**, D Anildes-Gubman, D McCall, K Faltus, S Featherston, B Shoberu , JR Moffet , D Petropoulos , SJ Khazal, S Razvi , KM Mahadeo, PTewari
Chimeric Antigen Receptor, Teamwork, Education, Assessment and Management (CAR-TEAM): A Simulation-based Inter-Professional Education (IPE) Intervention for Management of CAR-Toxicities. Frontiers in Oncology. Aug 2020.PMID 32850365
7. L Dao, **D Ragoonanan (co first author)**, S Yi, R Swinford, D Petropoulos, KM Mahadeo, S Li
The Organ Trail: A Review of Biomarkers of Organ Failure. Frontiers in Oncology.Nov 2020. PMID: 33262945
8. **D Ragoonanan**, F P Tambaro, S.J Khazal, P Tewari, D Petropoulos, R Champlin, K M Mahadeo
Cytokine Release Syndrome and Complete Remission of Extra Medullary Acute Lymphoblastic Leukemia of the Breast with Chimeric Antigen Receptor Therapy –Pediatric Blood and Cancer. Dec 2020. PMID: 33258192
9. **D Ragoonanan**, SJ Khazal, R Mejia, LEwing, JB Durand, L Bashoura, JH Tayar, N Dailey-Garnes, DPetropoulos, PTewari, MM Bhatti, A Haider Ahmad, J Cortes, S Razvi, K McBeth, R Swinford, B Shoberu, W Waseemuddin, L Chi, J Gill, W Zaky, N Daw, C Gutierrez, W Tereffe, P Kebriaei, K Rezvani, EJ Shpall, R Champlin, KM Mahadeo
Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)- Frontiers Oncol. 2021 Feb 4. PMID: 33614514
10. FP Tambaro, **D Ragoonanan**, P Tewari, D Petropoulos, FM Aung, KM Mahadeo, S Khazal
The Role of Granulocyte Transfusions in Optimizing Candidacy for Chimeric Antigen Receptor T-Cell Therapy in Patients With Treatment-refractory Infections. J Pediatr Hematol Oncol. 2022 Mar
PMID: 33625094
11. **D Ragoonanan**, SJ Khazal, H Abdel Azim, D McCall, B Cuglievan, F Paolo Tambaro, A Haider Ahmad, C Rowan, C Gutierrez, KSchadler, S Li, M DiNardo, L Chi, AM Gulbis, B Shoberu, M E. Mireles, J McArthur ,N Kapoor, J Miller, J C. Fitzgerald, P Tewari, D Petropoulos, JB.Gill, C N.

Duncun , L E. Lehmann SHingorani, JR. Angelo, RD Swinford, ME. Steiner, F Hernandez Tejada , PL. Martin, J Auletta,S Won Choi ,Rr Bajwa, NDailey-Games,P Kebraie, K Rezvani, WG. Wierda, SS.Neelapu , EJ Shpall, S Corbacioglu, KM. Mahadeo

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer- Nature Reviews Clinical Oncology. 2021 Feb 19. PMID: 33608690

12. A Gibson, **D Ragoonanan**, P Tewari, D Petropoulos, N Rodriguez, C DiNardo, KM Mahadeo, S Khazal
Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita Pediatr Transplant. 2021; PMID: 34626046
13. L Dao, **D Ragoonanan (co-first author)**, I Batth, J Wang, J Foglesong, W Zaky, A Albert, N Gordon, W Huh, D Harrison, E Kleinerman, S Li.
Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Front Oncol. 2021; PMID: 34956881
14. I Sheikh, **D Ragoonanan**, A Franklin, C Srinivasan, B Zhao, D Petropoulos, KM Mahadeo, P Tewari, SJ Khazal
Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature. Cancers (Basel). 2021; PMID: 34830969
15. Zhiliang Jia, **Dristhi Ragoonanan**, Kris Michael Mahadeo , Jonathan Gill , Richard Gorlick , Elizabeth Shpal , Shulin Li.
IL12 immune therapy clinical trial review. Novel strategies for avoiding CRS associated cytokines. Front Immunol.2022. PMID: 36203573
16. Irtiza N Sheikh, Amr Elgehiny , **Dristhi Ragoonanan** , Kris M Mahadeo , Yago Nieto , Sajad Khazal. **Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.** Cancers(Basel).2022; PMID:35740580
17. Irtiza N Sheikh, Shaikha Alqahtani , **Dristhi Ragoonanan** , Priti Tewari , Demetrios Petropoulos , Kris M Mahadeo , Uday Popat , Elizabeth J Shpall , Sajad Khazal
Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia. Int J Mol Sci. 2022. PMID:35955881
18. **Ragoonanan D**, Sheikh IN, Gupta S, Khazal SJ, Tewari P, Petropoulos D, Li S, Mahadeo KM.
The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Biomedicines.2022 PMID 36140387
19. **Ragoonanan D**, Bhar S, Mohan G, Beltramo F, Khazal SJ, Hurley C, Andersen C, Margossian S, Neelapu SS, Shpall E, Gutierrez C, Tewari P, Shoberu B, Talleur A, McCall D, Nunez C, Cuglievan B, Tambaro FP, Petropoulos D, Abdel-Azim H, Mahadeo KM. **A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy.** Fron Oncology 2022 Oct PMID 36353531
20. Ariagno S, **Ragoonanan D**, Khazal S, Mahadeo KM, Cisneros GS, Zinter MS, Blacken RA, Mohan G, Lehmann LE, Ferdjallah A, Mara KC, Kohorst MA. **Prior COVID-19 infection may increase risk for developing endothelial dysfunction following hematopoietic cell transplantation .**Fron Oncology 2023 Jan PMID: 36733348
21. Branko Cuglievan, Jeremy Connors, Jiasen He, Sajad Khazal, Sireesha Yedururi, Julia Dai, Sofia Garces, Andres E. Quesada, Michael Roth, Miriam Garcia, David McCall, Amber Gibson, **Dristhi Ragoonanan**, Demetrios Petropoulos, Priti Tewari, Cesar Nunez, Kris M. Mahadeo, Sarah K. Tasian, Adam J. Lamble, Anna Pawlowska, Danielle Hammond, Abhishek Maiti, Fadi G. Haddad, Jayatsu Senapati, Naval Daver, Naseema Gangat, Marina Konopleva, Soheil Meshinchi & Naveen Pemmaraju .**Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies.** Leukemia 2023 July, PMID:37452102
22. Wafik Zaky, Dristhi Ragoonanan, Izhar Batth, Long Dao, Jian Wang ,Xueqing Xia ,Najat C. Daw,Jonathan B. Gill ,Soumen Khatua, Shulin Li
Automated Capture and Analysis of Circulating Tumor Cells in Pediatric, Adolescent and Young Adult Patients with Central Nervous System Tumors. Cancers 2023, July PMID: 37568669

23. Jiasen He, Faryal Munir, **Dristhi Ragoonanan**, Wafik Zaky, Sajad J Khazal, Priti Tewari , Juan Fueyo, Candelaria Gomez-Manzano and Hong Jiang
Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. Immuno, 2023 Jan

Expert Commentary on Publications

“The coming of age of the pediatric EBMT criteria” (PMID: 33221818) published in Bone Marrow Transplantation, written by Professor Selim Corbacioglu (the Chair of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and one of the international leading experts in this field) on my publication “Improved Detection of Sinusoidal Obstructive Syndrome Using Pediatric- AYA Diagnostic Criteria and Severity Grading”

Book Chapters

1. SJ Khazal SJ, **D Ragoonanan**, J Hume, C Rowan, KM Mahadeo
Chapter 40: Care of the Critically Ill Pediatric Hematopoietic Cell Transplant Patient in: Pediatric Critical Care: Text and Study Guide, Second Edition. Publisher: Springer. 2021 ISBN 978-3-030-53363-2
2. **D Ragoonanan**, B Brown. K Mahadeo
Chapter 39: Miscellaneous Complications of Hematopoietic Cellular Transplantation in the Manual of Stem Cell Transplantation and Cellular Therapies for Hematologic Malignancies. Publisher: Elsevier

Invited Book Chapters Awaiting Publication

N Daw, **D Ragoonanan**

Chapter 526: Neoplasms of the Kidney in Nelson Textbook of Pediatrics, 22nd Edition
Publisher: Elsevier

Editorial and Review Activities

Journal reviewer

Reviewer, Translational Pediatrics, 2023

Oral Presentations

National and International Conferences

- | | |
|--|---------|
| Prevalence of Triple Negative Breast Cancer in Trinidad
A review of 1500 breast cancer cases Caribbean College of Surgeons Meeting. Tobago | 08/2010 |
| Diagnostic Criteria for Sinusoidal Obstructive Syndrome in Pediatrics
Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Vancouver, BC | 09/2019 |
| Education for the Clinical Implementation of CAR-T Cell Therapy using Simulation Based Education for Evidence Based Management of Chimeric Antigen Receptor T-cell Related Cytokine Release Syndrome and Encephalopathy Syndrome.
European Society for Blood and Marrow Transplantation and European Hematology Association/European CAR T Cell Meeting. Best Abstract and Flash Talks Session Oral Presentation. Sitges, Barcelona, Spain | 01/2020 |
| Predictors of Outcomes for Patients with Acute Lymphoblastic Leukemia Post Chimeric Antigen Receptor T-Cell Therapy | 02/2020 |

Center for International Blood and Marrow Transplant Research. Orlando, FL

Organ Failure Assays Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) New Orleans, LA	03/2020
Sinusoidal Obstructive Syndrome. A Single Center Retrospective Review Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) New Orleans, LA	03/2020
Sinusoidal Obstructive Syndrome: A Multi Centre Retrospective Review Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Virtual Spring Meeting 2021	03/2021
ICU Resource Utilization In Pediatric And Adolescent Young Adult Patients Post CAR-T Therapy Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Virtual Spring Meeting 2021	03/2021
Center for International Blood and Marrow Transplant Research (CIBMTR) 2020 Pediatric Outcome Highlights Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Virtual Fall Meeting 2021	09/2021
ICU Resource Utilization In Pediatric And Adolescent Young Adult Patients Post CAR-T Therapy and Sinusoidal Obstructive Syndrome: Update on Multi Centre Retrospective Reviews Pediatric Acute Lung Injury and Sepsis Investigators (PALISI), San Diego, CA	03/2022
Institutional Conferences	
Cell Surface Vimentin Positive Circulating Tumor Cells as Biomarkers of Malignancy in the Pediatric and Adolescent and Young Adult Population Grand Rounds, MD Anderson Children's Cancer Hospital The University of Texas, Houston TX, USA	05/2021
Cell Surface Vimentin Positive Circulating Tumor Cells as Biomarkers of Malignancy in the Pediatric and Adolescent and Young Adult Population 10 th Annual Department of Pediatrics Fellow Research Symposium The University of Texas, Houston TX, USA	05/2021
<u>Poster Presentations/Abstracts</u>	
The Microbiological Profile of Diabetic Foot Sepsis and the Prevalence of MRSA at a Teaching Hospital in the Caribbean. Eric Williams Medical Sciences Complex Annual Research Conference. Trinidad and Tobago	08/2011
The Importance of Resident Confidence in Sharing Life Altering Information. American Academy of Pediatrics. Chicago, IL, USA	09/2017
Incomplete Kawasaki Disease in a 3-Month-Old. A Case Report Annual Henry Gelband Pediatric Research Symposium. University of Miami, Miami, FL, USA	04/2018
Improving Pain Assessment of Patients with Sickle Cell Disease Who Present with Vaso-Occlusive Episodes in the Emergency Department- A Quality Improvement Project Florida Chapter of the American Academy of Pediatrics. Orlando FL, USA	04/2018

Prevalence of Vitamin D Deficiency among Children and Young Adults with Sickle Cell Disease and its Relationship with Disease Severity.	04/2018
American Society of Pediatric Hematology/Oncology. Pittsburg, PA, USA	
Simulation Based Education For the Evidenced Based Management of Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome and Cytokine Release Syndrome	02/2019
American Society of Pediatric Hematology/Oncology, New Orleans, LA, USA	
The Efficacy of Simulation Based Education for the Evidenced Based Management of Venous-Occlusive Disease.	04/2019
6th Annual BCM Quality Improvement and Patient Safety Conference Houston, TX, USA	
Phase I Study of Intraventricular Infusions of Autologous Ex-vivo Expanded Natural Killer Cells in Children with Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System.	
American Association for Cancer Research. Atlanta, GA, USA	
Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson.	12/2019
American Society of Hematology. Orlando, FL, USA	
DNMT3A Mutations in Pediatric Acute Myeloid Leukemia May be Associated with Adverse Outcomes and Potentially Impact Risk Stratification.	06/2020
Pediatric Blood & Cancer, vol. 67, pp. S222-S222.	
Optimizing Vancomycin Dosing in the Pediatric Hematopoietic Stem Cell Transplant Population.	06/2020
Pediatric Blood & Cancer, vol. 67, pp. S220-s220.	
Pilot Study of Circulating Tumor Cells in Pediatric High-Grade Brain Tumors	12/2020
International Symposium on Pediatric Neuro-Oncology	
Embryonal Tumor with Multilayered Rosettes in Children: The MD Anderson Cancer Center Experience.	12/2020
International Symposium on Pediatric Neuro-Oncology	
ICU Resource Utilization In Pediatric And Adolescent Young Adult Patients Post CAR-T Therapy	03/2021
47th Annual Meeting of the European Society for Blood and Marrow Transplantation.	
Cell-surface Vimentin Positive Circulating Tumor Cells as a Diagnostic and Prognostic Indicator in Pediatric Sarcoma Patients	05/2021
Journal of Clinical Oncology 2021 39:15_suppl, e15022-e15022	
DNMT3A Mutations Should be Considered in the Risk Stratification for Pediatric and Adolescent and Young Adult Patients with Acute Myeloid Leukemia	12/2021
American Society of Hematology. Atlanta GA, USA	
Immune Reconstitution following Tisagenlecleucel in Pediatric, Adolescent, and Young Adult Patients with B Acute Lymphoblastic Leukemia	02/2022
American Society for Transplantation and Cellular Therapy. Salt Lake City, UT, USA	
Pre-transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation in Pediatric Patients with Hemoglobinopathies: Successful Engraftment	04/2022

and No Severe GVHD.

48th Annual Meeting: European Society for Blood and Marrow Transplantation. Virtual Meeting

Pediatric, Adolescent and Young Adult Patients with Acute Myeloid Leukemia and DNMT3A Mutations may have Improved Survival with Allogeneic Hematopoietic Stem Cell Transplant 04/2022

American Society for Transplantation and Cellular Therapy. Salt Lake City, UT, USA

CSV+ Circulating Tumor Cells as Biomarkers of Malignancies in the Pediatric and AYA Population 04/2022

American Society for Transplantation and Cellular Therapy. Salt Lake City, UT, USA

Quantitative and Qualitative Immune Reconstitution Analysis in an Adolescent Patient with Refractory Primary Mediastinal Large B Cell Lymphoma after Axicabtagene Ciloleucef CD19 CAR T-Cell Therapy. 04/2022
American Society for Transplantation and Cellular Therapy.
Salt Lake City, UT, USA

Prior COVID-19 Infection and Risk for Developing Endothelial Dysfunction Following Hematopoietic Cell Transplantation 05/2022

American Society Pediatric Hematology Oncology, Pittsburg PA

attIL12-T cell therapy destructs cancer-associated fibroblasts and extracellular matrix in heterogenous osteosarcoma xenograft models 04/2023

American Association for Cancer Research ,Orlando FL

Teaching/Presentations

External

Treatment options for a 13-month-old with AML and KMT2A MLL rearrangement
Hematopoietic Cellular Transplant, Multi Institutional Tumor Board, Department of Pediatrics, MD Anderson Cancer Center 06/2019

Management of a Patient with Possible Autoimmune Lymphoproliferative Syndrome
Hematopoietic Cellular Transplant, Multi Institutional Tumor Board, Department of Pediatrics, MD Anderson Cancer Center 06/2019

COVID-19 and its Impact on Children- Discussing the impact of COVID-19 in pediatrics, the potential negative social and emotional consequences and useful techniques to help children cope.
Webinar presented to the Energy Transfer Partners Group and their employees.
03/2021

Therapy Related AML in Pediatrics.
Hematopoietic Cellular Transplant, Multi Institutional Tumor Board, MD Anderson Cancer Center,10/2021

Pure Red Cell Aplasia Post Haploidentical Stem Cell Transplant for Sickle Cell Disease
Extension for Community Health Outcomes (ECHO) 02/2022

Diamond Blackfan Anemia and Allogeneic Stem Cell Transplant
Hematopoietic Cellular Transplant, Multi Institutional Tumor Board, MD Anderson Cancer Center,03/2022

Autologous Stem Cell Transplant for Wilms Tumor
Hematopoietic Cellular Transplant, Multi Institutional Tumor Board, MD Anderson Cancer Center,03/2022

Teaching within Current Institution- The University of Texas MD Anderson Cancer Center

Training Programs

Program Director, Pediatric Stem Cell Transplantation and Cellular Therapy Clinical Fellowship
7/2021-present

Other Formal Teaching

Chair, Multi-Institutional BMT Tumor Board, Course Hours: 1/month
8/2017-present

Chair, Pediatric Stem Cell Transplantation academic hour, Course Hours: 1/month
7/2019-present

Optic Gliomas. Neuro-oncology Tumor Board, Department of Pediatrics, MD Anderson Cancer Center 11/2018

Fever of Unknown Origin. Morbidity and Mortality Conference, Department of Pediatrics, MD Anderson Cancer Center 02/2019

Patient-Reported Quality of Life After Tisagenlecleucel Infusion in Children and Young Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia: A Global, Single-Arm, Phase 2 Trial. Journal Club, CARTOX Meeting, MD Anderson Cancer Center 02/2019

Critical Care Management of Pediatric HSCT and Cell Therapy Patients Workshop on Sinusoidal Obstructive Syndrome. Association of Pediatric Hematology/Oncology Nurses. Houston TX 02/2019

Phase I/Phase II Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal Club, Department of Pediatrics, MD Anderson Cancer Center 09/2019

Upper Airway Management. Morbidity and Mortality Conference, Department of Pediatrics, MD Anderson Cancer Center 11/2019

The Tyrosine Kinase Inhibitor Dasatinib Acts as a Pharmacologic On/Off Switch for CAR T cells. Journal Club, Department of Pediatrics, MD Anderson Cancer Center 11/2019

COVID-19 Review and Updates. Research Seminar, Department of Pediatrics, MD Anderson Cancer Center 05/2020

Dyskeratosis Congenita, Hematopoietic Cellular Transplant Tumor Board, Department of Pediatrics, MD Anderson Cancer Center, 05/2020

Glucocorticoid use in Acute Lymphoblastic Leukemia. Journal Club, Department of Pediatrics, MD Anderson Cancer Center 05/2020

Chimeric Antigen Receptor, Teamwork, Education, Assessment and Management (CAR-TEAM) A Simulation-based Inter-Professional Education Intervention for Management of CAR-Toxicities. Research Seminar, Department of Pediatrics, MD Anderson Cancer Center,06/2020

COVID-19 in Pediatrics. Research Seminar, Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, 06/2020

Hypovolemic Shock and Disseminated Intravascular Coagulation. Morbidity and Mortality Conference, Department of Pediatrics, MD Anderson Cancer Center 08/2020

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children, a randomized, controlled, phase 3 trial use in Acute Lymphoblastic Leukemia. Journal Club, Department of Pediatrics, MD Anderson Cancer Center 03/2021

A Review of Platelet Disorders.

Fellows Didactic Conference, Department of Pediatrics, MD Anderson Cancer Center 04/2021

Veno Occlusive Disease after Inotuzumab and Double Alkylator Conditioning Regimen Morbidity and Mortality Conference, Department of Stem Cell Therapy, MD Anderson Cancer Center 04/2021

Clonal Hematopoiesis in Hematopoietic Stem Cell Transplant.
Journal Club, Department of Pediatrics, MD Anderson Cancer Center 07/2021

Multidisciplinary Care of a Patient with Beta Thalassemia Major Post hematopoietic Stem Cell Transplantation.
Morbidity and Mortality Conference, Department of Stem Cell Therapy, MD Anderson Cancer Center 09/2021

Transplant-associated thrombotic microangiopathy (TA-TMA)
Fellows Didactic Conference, Department of Pediatrics, MD Anderson Cancer Center, 09/2021

Other Formal Teaching

Invited Lecturer to Residents: Department of Pediatrics, The University of Texas, Houston 2019-2021

Invited Lecturer to Medical Students: Mc Govern Medical School, The University of Texas, Houston. 2019-2020

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

American Academy of Pediatrics (AAP), Member as of 2015

Children's Oncology Group, Member as of 2018

American Society of Hematology (ASH), Member as of 2019

American Society of Pediatric Hematology Oncology (ASPHO), Member as of 2019

American Society for Transplantation and Cellular therapy (ASTCT), Member as of 2019

American Academy of Pediatrics (AAP), Section of Hematology/Oncology, Member as of 2020

PROFESSIONAL DEVELOPMENT

Service Excellence Training. MD Anderson Cancer Center. Houston TX 2019,2020

Vital Talk Workshop: Breaking Bad News. 12/2019

ECHO: Heal Sickle, A Multidisciplinary Workshop (2020-Present)

Trainee Leadership Certificate Program. 01/2021

Leading High-Performance Teams. 04/2021

Clinical Quality Improvement Certificate: 06/2021

Physician Educators Certificate Program (09/2021- Present): McGovern School of Medicine

Dare to Lead Program (10/2021-12/2021)

UNIQUE ACTIVITIES

Volunteer at the Houston Society for the Prevention of Cruelty to Animals: Foster Volunteer and Adoption Counsellor

Date of Last CV Update: 8/24/2023